N@N

50.78% Of All NASDAQ Trading Tuesday Was Short Selling. BPSG, SHAW, ELOS, EXEL, PRGO, BEBE % Of Daily Trading Volume Short

^{Published on 2009-09-16 08:41:20, Last Modified on 2010-12-22 14:44:26 - WOPRAI}
 

September 16, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, has reviewed the NASDAQ Daily Short Volume Report for Tuesday, September 15th, 2009 and come to the following statistical conclusions. There were 6,769 stocks with daily short volume reported and total NASDAQ trading volume of 1,861,923,511 shares. Total Daily Short Volume was 945,541,363 shares. 50.78% of all trading on the NASDAQ Tuesday was short selling. The chart below highlights 6 stocks that had unusually high percentages of their total daily trading volume attributed to short sales. Broadpoint Gleacher Securities Group (NASDAQ: BPSG), Shaw Group (NASDAQ: SHAW), Syneron Medical (NASDAQ: ELOS), Exelixis (NASDAQ: EXEL), Perrigo (NASDAQ: PRGO) and Bebe Stores (NASDAQ: BEBE). To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

DATE SYMBOL SHORT VOLUME TOTAL VOLUME MARKET PERCENT

20090915 BPSG 171,497 213,518 Q 80.32%

20090915 SHAW 116,240 148,998 Q 78.01%

20090915 ELOS 121,432 156,105 Q 77.79%

20090915 EXEL 166,409 216,536 Q 76.85%

20090915 PRGO 214,421 285,430 Q 75.12%

20090915 BEBE 106,384 142,295 Q 74.76%

In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesa� naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.

Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.

The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.

Broadpoint Gleacher Securities Group, Inc. (NASDAQ: BPSG) provides independent advice and execution in the areas of advisory services; capital raising; and research, sales, and trading to corporate and institutional clients primarily in the United States. The company also offers mergers and acquisitions advisory services, as well as restructuring and recapitalization advisory services to a range of constituents, including corporations, creditors, labor related parties, government agencies, litigation claimants, plan sponsors and stalking horse bidders, or other potential acquirers. In addition, it underwrites and places initial public offerings, follow-on public equity offerings, secondary equity offerings and direct registered placements of equity securities, and private placements of public and private equity and hybrid securities; underwrites and places public and private placements of investment grade debt, high yield debt, bank debt and convertible debt, and various other fixed income related securities; and provides liability management advisory and execution services. Further, Broadpoint Gleacher Securities Group offers proprietary debt and equity research, broad and differentiated institutional account coverage, and trading execution services for institutional investors. The company was formerly known as Broadpoint Securities Group, Inc. and changed its name to Broadpoint Gleacher Securities Group, Inc. in June 2009. Broadpoint Gleacher Securities Group, Inc. was founded in 1952 and is headquartered in New York, New York.

The Shaw Group, Inc. (NASDAQ: SHAW) offers engineering, technology, construction, fabrication, environmental, and industrial services to various companies worldwide. The companya�s Fossil and Nuclear segment provides project-related services, including design, engineering, construction, procurement, technology, and consulting services to the fossil and nuclear power generation industries. Its Environmental and Infrastructure segment designs and executes remediation solutions involving contaminants in soil, air, and water. This segment also provides project and facilities management, and other related services for non environmental construction, emergency response, and watershed restoration, as well as program and construction management, and operations and maintenance solutions to support and enhance land, water, and air transportation systems. The Shaw Groupas Energy and Chemical segment offers project-related services, such as design, engineering, construction, procurement, technology, and consulting services to the oil and gas, refinery, petrochemical, and chemical industries. The companya�s Maintenance segment provides its clients with reliability services, turnarounds and outage services, capital construction, tank design construction and maintenance, architectural and building services, off-site modularization, and specialty services. Its Fabrication and Manufacturing segment supplies fabricated piping systems. In addition, The Shaw Group supplies nuclear plant designs, licensing, engineering, equipment, fuel, and other products and services to the owners and operators of nuclear power plants. The companya�s customers include multinational oil companies and industrial corporations, regulated utilities, independent and merchant power producers, governmental agencies, and other equipment manufacturers. It markets its services through an in-house sales force and through independent contractors. The company was founded in 1987 and is headquartered in Baton Rouge, Louisiana.

Syneron Medical Ltd. (NASDAQ: ELOS) designs, develops, and markets aesthetic medical products. The company develops products based on its proprietary ELOS technology, which combines conducted radiofrequency energy, an electrical energy; and light or laser-based energy, an optical energy. Its products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skina�s appearance, acne treatment, leg veins treatment, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, skin tightening, laser-assisted lipolysis, and dental laser. The company sells its products primarily to physicians and other practitioners, including plastic surgeons, aestheticians, medical spas, dentists, dermatologists, and cosmetic physicians. Syneron Medical Ltd. sells its products through a direct sales force in the United States and Canada, and through distributors in Europe, the Middle East, South Africa, the Asia-Pacific region, and South and Central America. The company was founded in 2000 and is headquartered in Yokneam Illit, Israel.

Exelixis, Inc. (NASDAQ: EXEL) discovers and develops small molecule drugs for the treatment of cancer, and various metabolic and cardiovascular disorders. Its products include XL184, a Phase 3 clinical trial compound that inhibits MET, RET, and VEGFR2, which drive tumor growth and vascularization, as well as Phase 1b/2 clinical trials compounds, including XL147 that targets phosphoinosotide-3 kinase (PI3K); and XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway. The company has various compounds in phase 1 clinical trials, including XL518, a small molecule inhibitor of the MEK, a component of the RAS/RAF/MEK/ERK signaling pathway; XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a range of human tumors; XL019 that inhibits JAK2, a cytoplasmic tyrosine; XL139, which inhibits activation of Hedgehog signaling; XL413, a small molecule inhibitor of the serine-threonine kinase CDC7; and XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases. In addition, its preclinical and clinical development stage products that are out-licensed to third parties for the development and commercialization include XL880, an inhibitor of MET and VEGFR2; XL281, which targets RAF, a cytoplasmic serine/threonine kinase; XL652 targeting liver X receptors, which modulate genes involved in regulation of lipid and cholesterol homeostasis; XL550, a non-steroidal mineralocorticoid receptor; and FXR Program that targets Farnesoid X Receptor, a bile acid receptor. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; and Daiichi-Sankyo. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Perrigo Company (NASDAQ: PRGO), through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, active pharmaceutical ingredients (API), and medical diagnostic products worldwide. The company operates through three segments: Consumer Healthcare, Rx Pharmaceuticals, and API. The Consumer Healthcare segment offers OTC pharmaceutical and nutritional products, which include analgesic, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, first aid, and vitamin and nutritional supplement products. The Rx Pharmaceuticals segment develops, manufactures, and markets generic prescription drug products, including creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquid suspensions, and solutions, as well as nasal sprays, oral liquids, and transdermal products. The API segment engages in the development, manufacture, and marketing of APIs used by the generic drug industry and branded pharmaceutical companies. Perrigo Company also manufactures and markets branded prescription drugs; and imports pharmaceutical, diagnostics, and other medical products. The company has collaborative agreements with Medicis Pharmaceutical Corporation, Medimetriks Pharmaceuticals, Cobrek Pharmaceuticals, and Cephalon Inc. Its customers primarily include retail drug companies, supermarkets, wholesalers, chain drug stores, hospitals and hospital systems, mass merchandise chains, and group purchasing organizations. The company was founded in 1887 and is headquartered in Allegan, Michigan.

Bebe stores, inc. (NASDAQ: BEBE) engages in the design, development, and production of womena�s apparel and accessories. Its products include a range of separates, tops, dresses, active wear, and accessories in career, evening, casual, and active lifestyle categories. The company markets its products under the bebe, COLLECTION bebe, BEBE SPORT, bbsp, bebe O, and 2b bebe brand names primarily through retail stores. As of July 5, 2008, bebe stores, inc. operated 303 specialty retail stores, including 212 bebe stores, 63 BEBE SPORT stores, 20 bebe outlet stores, 7 2b bebe stores, and an on-line store at www.bebe.com in the United States, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and Canada. It also markets its products through its online store at bebe.com, and through its 21 international licensee operated stores. The company was founded in 1976 and is headquartered in Brisbane, California.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies or third parties pay $995 per month to purchase data for information provided in monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net